News & Updates

Is vitiligo as side effect a good sign for cancer patients on immunotherapy?

03 Apr 2025 by

Vitiligo occurs as a cutaneous immune-related adverse event during immune checkpoint inhibitor (ICI) therapy in most melanoma and nonmelanoma cancer patients with partial or complete response to treatment, according to a systematic review.

Is vitiligo as side effect a good sign for cancer patients on immunotherapy?

03 Apr 2025

Early-onset AD tied to higher risk of atopic march in children

02 Apr 2025

Children with early-onset atopic dermatitis (AD) are at increased odds of developing atopic march conditions compared with those with early-onset AD, reveals a study.

Early-onset AD tied to higher risk of atopic march in children

02 Apr 2025

Biosimilar as safe, effective as ustekinumab in plaque psoriasis

31 Mar 2025

The biosimilar BAT2206 demonstrates similar efficacy, safety, pharmacokinetics, and immunogenicity to its reference drug, ustekinumab (UST), in a recent phase III trial.

Biosimilar as safe, effective as ustekinumab in plaque psoriasis

31 Mar 2025

Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab

28 Mar 2025 by

The use of lebrikizumab improves the symptoms of moderate-to-severe atopic dermatitis (AD) in patients previously treated with dupilumab, reports a study presented at AAD 2025.

Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab

28 Mar 2025

Skin fairness creams not fair to the kidneys

28 Mar 2025 by

A recent review integrates multiple research findings and turns the spotlight on the growing nephrotoxic threat posed by skin-whitening creams.

Skin fairness creams not fair to the kidneys

28 Mar 2025

Remibrutinib improves sleep, daily activities in patients with CSU

28 Mar 2025 by

Treatment with remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, improved sleep and daily activities in patients with chronic spontaneous urticaria (CSU), according to two phase III REMIX-1 and -2 studies presented at AAD 2025.

Remibrutinib improves sleep, daily activities in patients with CSU

28 Mar 2025

Apremilast boasts long-term improvement in PPP

27 Mar 2025 by

Patients with palmoplantar pustulosis (PPP) treated with apremilast show improvements at week 16, with continued treatment resulting in maintained or further improvement at week 52, according to a study presented at AAD 2025. No new safety concerns have been observed.

Apremilast boasts long-term improvement in PPP

27 Mar 2025

Baricitinib tied to hair regrowth in adolescents with severe AA

26 Mar 2025 by

Once-daily treatment with baricitinib resulted in clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes among adolescent patients with severe alopecia areata (AA), according to the BRAVE-AA-PEDS trial presented at AAD 2025.

Baricitinib tied to hair regrowth in adolescents with severe AA

26 Mar 2025

Eyebrow or eyelash hair loss affects QoL in AA patients

25 Mar 2025 by

A real-world analysis presented at AAD 2025 shows that patients with alopecia areata (AA) with eyebrow or eyelash hair loss have greater health-related quality of life (HRQoL) burden than those without eyebrow and eyelash involvement.

Eyebrow or eyelash hair loss affects QoL in AA patients

25 Mar 2025

Anti–IL-23 monoclonal antibody promising in plaque psoriasis

24 Mar 2025

The investigational anti–IL-23 monoclonal antibody QX004N appears to be well tolerated and have superior efficacy vs placebo in the treatment of patients with moderate to severe plaque psoriasis, according to a phase I study from China.

Anti–IL-23 monoclonal antibody promising in plaque psoriasis

24 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Is vitiligo as side effect a good sign for cancer patients on immunotherapy?

Is vitiligo as side effect a good sign for cancer patients on immunotherapy?

Early-onset AD tied to higher risk of atopic march in children

Early-onset AD tied to higher risk of atopic march in children

Biosimilar as safe, effective as ustekinumab in plaque psoriasis

Biosimilar as safe, effective as ustekinumab in plaque psoriasis

Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab

Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab

Skin fairness creams not fair to the kidneys

Skin fairness creams not fair to the kidneys

Remibrutinib improves sleep, daily activities in patients with CSU

Remibrutinib improves sleep, daily activities in patients with CSU

Apremilast boasts long-term improvement in PPP

Apremilast boasts long-term improvement in PPP

Baricitinib tied to hair regrowth in adolescents with severe AA

Baricitinib tied to hair regrowth in adolescents with severe AA

Eyebrow or eyelash hair loss affects QoL in AA patients

Eyebrow or eyelash hair loss affects QoL in AA patients

Anti–IL-23 monoclonal antibody promising in plaque psoriasis

Anti–IL-23 monoclonal antibody promising in plaque psoriasis